

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/527,442	03/17/2000	Thomas P. Jerussi	4821-369-999	3088
20582 7	590 03/25/2003			
PENNIE & EDMONDS LLP 1667 K STREET NW SUITE 1000 WASHINGTON, DC 20006			EXAMINER	
			BARTS, SA	AMUEL A 14
WASHINGTO	N, DC 20006		ART UNIT	PAPER NUMBER
			1621	

DATE MAILED: 03/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/527,442	JERUSSI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Samuel A Barts	1621				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for R ply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on <u>02 J</u>	anuary 2003 .					
2a)⊠ This action is <b>FINAL</b> . 2b)□ Thi	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims						
4)⊠ Claim(s) <u>27-29 and 52-59</u> is/are pending in the	e application.	•				
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>27-29 and 52-59</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:						
,_ ,_ ,_ ,_	a have been received					
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

#### DETAILED ACTION

### Response to Arguments

Applicant's arguments filed January 2, 2003 have carefully been considered and were found not to be persuasive.

Applicants argued that "Taft does not describe the administration of a venlafaxine derivative such as ODV to humans". The examiner does not agree. Taft administers ODV via the oral compositions of venlafaxine. The property of ODV as an antidepressant is clearly stated in Taft et al. "ODV is a compound with antidepressant activity comparable with the parent drug". Therefore, Taft et al were well aware of the antidepressant activity of ODV. They were also well aware that ODV is a major metabolite in the first pass metabolism by the liver of the drug venlafaxine. Thus, Taft et al teach that one would administer ODV inherently when giving the parent drug venlafaxine. It is well settled that a prior art reference may anticipate when the claim limitations not expressly found in that reference are nonetheless inherent in it. "Under the principle of inherency, if the prior art necessarily functions in accordance with, or includes, the claimed limitations it anticipates." MEHL/Biophile Int'l Corp. V. Miltraum, 192 F.3d 1362, 1365, 52 USPQ2d 1303, 1305.

Also, note the statement <u>"ODV is a compound with antidepressant activity</u> comparable with the parent drug," teaches that it was well known at the time that applicant's invention was filed that ODV is an antidepressant. The disease

Application/Control Number: 09/527,442

Art Unit: 1621

itself implies the use in humans. Depression is a human disease exclusively. One definition of depression is " A state of deep dejection and pervasive feeling of helplessness, accompanied by apathy ad a sense of personal worthlessness, resulting in retardation of thought and bodily functions", Cambridge dictionary of Science and Technology; copy right 1990).

Applicant's argument with respect to the 103 rejection is again the position that the prior art does not disclose all the limitations of the claimed invention.

As stated above the examiner does not agree with this argument because all the claimed limitations are inherent the disclosure of Taft et al.

The rejection is being maintained.

# Claim Rejections - 35 USC § 102

- 1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 2. Claim27-29 and 52-59 are rejected under 35 U.S.C. 102(b) as being anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Taft et al. For reasons see above response and prior office action.

#### Conclusion

3. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/527,442

Art Unit: 1621

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel A Barts whose telephone number is 703-308-4630. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johan Richter can be reached on 308-1235. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Page 5

Samuel A Barts Primary Examiner Art Unit 1621

s.b. March 12, 2003